Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Multiple Myeloma 2Lymphoma 2Sarcoma 1Preleukemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Osteosarcoma 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Myelodysplastic Syndromes 1Mobility Limitation 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, B-Cell, Marginal Zone 1Lymphatic Diseases 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia, B-Cell 1Leukemia 1Kidney Neoplasms 1Immunoproliferative Disorders 1Immune System Diseases 1Hematologic Diseases 1Head and Neck Neoplasms 1Esophageal Neoplasms 1

Interventions

pembrolizumab 22Nivolumab 14enfortumab vedotin 13Gemcitabine 11Specimen Handling 9Magnetic Resonance Spectroscopy 9Cisplatin 8Carboplatin 8sacituzumab govitecan 6avelumab 6Docetaxel 6atezolizumab 5Ipilimumab 5durvalumab 4Paclitaxel 4cabozantinib 3Taxes 3Mitomycin 3CTLA-4 Antigen 3tislelizumab 2relatlimab 2erdafitinib 2disitamab vedotin 2Radiosurgery 2Platinum 2Oxaliplatin 2Immunoglobulin G 2Fluorouracil 2Disulfides 2ALT-803 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Patient Reported Outcome Measures × 90 days × Clear all
NCT04146064 2026-05-08

Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response

University Health Network, Toronto

Completed
190 enrolled
DermatologicGenitourinaryHead & Neck

Carcinoma, Transitional Cell, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡